PMCB YT .png
PharmaCyte Biotech CEO Discusses Navigating Testing and IND Submission During COVID-19 Pandemic
March 26, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, March 26, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) continues to work with consultants to prepare its Investigational New Drug application (IND).  At the same time,...
PMCB YT .png
PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
January 27, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical...
PMCB YT .png
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
January 14, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
PMCB YT .png
PharmaCyte Biotech Finalizes Pancreatic Cancer Treatment for U.S. FDA Approval to Begin Clinical Trial
December 11, 2019 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Dec. 11, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a clinical trial product, a clinical trial protocol, including a clinical trial design, a Principal Investigator,...
PMCB YT .png
PharmaCyte Biotech’s “Release Testing” Last Critical Event Before Submission of Investigational New Drug Application
November 12, 2019 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Nov. 12, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can...
PMCB YT .png
PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial
October 28, 2019 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable...